Diacetoxyscirpenol

Urinary DAS is an exploratory exposure marker. A reliably confirmed detection supports exposure, but the result hasn't been validated to diagnose poisoning, explain symptoms, or predict future illness. Urinary mycotoxin detection also cannot establish that a building caused your exposure. CDC assessment of urine mycotoxin testing

This test reports DAS itself in urine, adjusted for urine creatinine. Its breakdown products are separate molecules. The catalog doesn't specify the laboratory method, so findings from research assays cannot establish how accurately this particular test identifies or measures DAS.

Where This Toxin Comes From

DAS belongs to the trichothecene family of mold toxins. Fusarium molds produce it, and it occurs mainly in cereal grains such as wheat, barley, oats, and corn. EFSA risk assessment

What a Urine Result Captures

Animal studies suggest that DAS is processed and excreted quickly. Those findings don't establish how long it remains detectable in human urine after a meal. A fixed one- or two-day detection window isn't justified, and a urine concentration cannot quantify how much toxin has accumulated in your body. EFSA assessment of absorption and excretion

Experiments using isolated human liver enzymes show that DAS can be converted into several breakdown products, including 15-monoacetoxyscirpenol, or 15-MAS. These were laboratory experiments, not measurements of what people excreted after eating contaminated food. They help explain why measuring DAS alone may miss some exposure, but they don't establish what fraction of an ingested dose appears in human urine. Yang and colleagues' metabolism study

What Human Studies Have Found

Published studies have reported DAS in human urine. The findings include both targeted measurements and tentative identifications from broader screening, which carry different levels of analytical certainty.

These results don't establish how often DAS would be detected by your laboratory. Collection protocols, chemical identification criteria, and detection limits differ. Neither study established a urinary DAS concentration that predicts illness. European exposure study, Spanish analytical study

A separate study tested plasma from 93 people with Alzheimer's disease, Parkinson's disease, or neither condition and found no DAS. Plasma is a different part of blood from the urine specimen used here. Its results cannot establish how commonly DAS appears in urine or how to interpret your urine concentration. Arce-López and colleagues' plasma study

Health Effects and What Is Still Unknown

Laboratory and animal studies show that DAS interferes with protein production and can damage the gut lining and blood-forming tissues. EFSA toxicology assessment

There is direct evidence of toxicity in people, too. DAS was studied as an experimental cancer drug under the name anguidine. Intravenous treatment caused nausea, vomiting, diarrhea, low blood pressure, and suppression of blood-cell production. Those drug doses and that route of exposure differ substantially from eating trace amounts in food. The trials did not establish a relationship between urine DAS levels and harm. Phase I clinical evaluation of anguidine

In its 2018 assessment, EFSA found no health concern from estimated dietary exposure in Europe, while noting limited contamination data. That population assessment doesn't provide a clinical interpretation for an individual urine result. EFSA risk assessment

When Results Can Be Misleading

• Which molecule was measured: DAS and 15-MAS are separate compounds. Results for one cannot be substituted for the other, and a panel's combined trichothecene result doesn't necessarily identify DAS. Metabolism study
• How identification was confirmed: a tentative signal from a broad chemical screen carries less certainty than a result from a method specifically validated to identify and quantify DAS in urine. The method used for this catalog test is unspecified. Urine screening study
• Collection and timing: a single urine sample and a full day's collection represent different sampling periods. Published detection rates from one protocol shouldn't be treated as the expected result from another. European collection study
• Creatinine adjustment: expressing the result per gram of creatinine helps account for urine dilution, but muscle mass, age, and kidney function can influence that adjustment. It doesn't make every person's result directly comparable. Study of urinary creatinine adjustment

What a Trend Can Mean

The available studies don't establish how much change in urinary DAS exceeds ordinary variation within one person, or whether a falling result means your health has improved. A series of measurements can document laboratory findings over time, but it hasn't been validated as a measure of recovery or a treatment target. Repeated-collection exposure study